» Articles » PMID: 31106370

Snail1-dependent Cancer-associated Fibroblasts Induce Epithelial-mesenchymal Transition in Lung Cancer Cells Via Exosomes

Overview
Journal QJM
Specialty General Medicine
Date 2019 May 21
PMID 31106370
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epithelial-mesenchymal transition (EMT) is an essential component of metastasis. Our previous study demonstrated that cancer-associated fibroblasts (CAFs) induce EMT in lung cancer cells. In recent years, many studies have demonstrated that CAFs induce metastasis and drug resistance in cancer cells via exosomes.

Aim: We sought to discover the mechanism underlying how CAFs induce EMT in lung cancer cells, unveiling the role of exosomes in lung cancer progression.

Design: We cultured lung cancer cell (i) with control medium, normal fibroblasts (NFs) or CAFs; (ii) with SNAI1-transfected or NC (negative control)-transfected CAFs; (iii) with exosomes extracted from NF- or CAF-conditioned medium; (iv) with exosomes released by SNAI1 or NC-transfected CAFs; (v) with CAF-conditioned medium or exosome-depleted CAF-conditioned medium.

Methods: qRT-PCR was conducted to examine the expression of CDH1 (gene of E-cadherin) and VIM (gene of Vimentin), western blotting was conducted to examine E-cadherin and vimentin levels in lung cancer cells.

Results: Exosomes released by CAFs-promoted EMT in lung cancer cells. Interestingly, SNAI1 levels in exosomes secreted from CAFs were correlated with SNAI1 expression in CAFs. Furthermore, the level of SNAI1 in exosomes was crucial for inducing EMT in lung cancer cells. Finally, treatment of CAFs with GW4869, an inhibitor of exosome release, noticeably inhibited their EMT-inducing effect on recipient epithelial cells.

Conclusions: The molecular mechanism underlying how CAFs induce EMT in cancer cells may be that CAFs deliver SNAI1 to recipient cancer cells via exosomes.

Citing Articles

Tumor necrosis factor receptor-associated factor 5 enhances perianal fistulizing Crohn's disease through epithelial-mesenchymal transition.

Sun X, Gao H, Lu L, Wang Q, Li Y, Gu Y Cytojournal. 2025; 21:82.

PMID: 39917000 PMC: 11801662. DOI: 10.25259/Cytojournal_148_2024.


Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method.

Feng Q, Shan X, Yau V, Cai Z, Xie S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861125 PMC: 11769033. DOI: 10.3390/ph18010062.


Heterogeneity and therapeutic implications of cancer-associated fibroblasts in lung cancer: Recent advances and future perspectives.

Yang C, Liu W, Powell C, Wang Q Chin Med J Pulm Crit Care Med. 2025; 2(4):240-249.

PMID: 39834587 PMC: 11742357. DOI: 10.1016/j.pccm.2024.08.009.


Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.


Comparative proteomic analysis between tumor tissues and intratumoral exosomes from lung adenocarcinoma patients identifies PAFAH1B3 as an exosomal protein key for initiating metastasis in lung adenocarcinoma.

Wang C, Xiao L, Gao L, Wu J, Wang S, Zheng M Heliyon. 2024; 10(21):e39859.

PMID: 39553628 PMC: 11567031. DOI: 10.1016/j.heliyon.2024.e39859.